Nā hopena kiʻekiʻe mai ka mālama ʻana i nā hōʻailona menopause

A HOLD Hoʻokuʻu ʻole 4 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ua hoʻolaha ʻo Astellas Pharma Inc. i kēia lā i nā hopena topline mai ka Phase 3 SKYLIGHT 4™ hoʻokolohua hoʻokolohua e noiʻi ana i ka palekana no ka wā lōʻihi o ka fezolinetant, kahi hui waha, nonhormonal noiʻi e aʻo ʻia no ka mālama ʻana i nā hōʻailona vasomotor haʻahaʻa a koʻikoʻi e pili ana me ka menopause (VMS). e kākoʻo i ka waiho ʻana i nā palapala hoʻoponopono e hiki mai ana. ʻO ka VMS, i hōʻike ʻia e ka wela wela (kahi i kapa ʻia ʻo ka wela wela) a / a i ʻole ka wela o ka pō, ʻo ia nā hōʻailona maʻamau o ka menopause.1,2      

ʻO SKYLIGHT 4 kahi hoʻāʻo hoʻokolohua hoʻokolohua hoʻokolohua ma kahi o 3 mau wahine e noiʻi ana i ka palekana o ka fezolinetant no ka wā lōʻihi (1,800-wiki) i nā wahine e ʻimi nei i ka lāʻau lapaʻau no ka hoʻomaha ʻana i ka VMS pili me ka menopause. ʻO nā pahuhopu nui o ka haʻawina ʻo ia ka loiloi i ka hopena o ka fezolinetant ma ke olakino endometrial a me ka palekana a me ka hoʻomanawanui lōʻihi o ka fezolinetant. Ua hoʻokō ʻia ka helu hope mua e nānā ana i ke olakino endometrial a ʻo ka mālama maʻamau emergent adverse events (TEAE) he poʻo poʻo a me COVID-52, kūlike me ka placebo. Hōʻike hou ka ʻikepili topline i ka ʻike palekana lōʻihi o ka fezolinetant a e hoʻomaopopo i nā faila hoʻoponopono e hiki mai ana. E waiho ʻia nā hopena kikoʻī no ka paʻi ʻana a no ka noʻonoʻo ʻana i nā hālāwai olakino e hiki mai ana.

"Ma muli o kā mākou loiloi mua, hauʻoli mākou i ka hopena o ka haʻawina SKYLIGHT 4, kahi e hōʻike hou ai i ka palekana lōʻihi o ka fezolinetant," wahi a Nancy Martin, MD, PharmD, Hope Pelekikena, Global Medical Head, Medical Specialties, Astellas . "Me kēia mau ʻikepili fezolinetant, manaʻolana mākou e loaʻa iā mākou ka manawa e hāʻawi i kahi koho lapaʻau nonhormonal mua i ka papa no ka VMS maʻalahi a koʻikoʻi e pili ana me ka menopause."

"Ua hōʻike pinepine ʻia nā hōʻailona Vasomotor e like me nā hōʻailona pilikia loa o ka menopause, akā naʻe he liʻiliʻi loa nā mea hou i kēia wahi therapeutic," wahi a Genevieve Neal-Perry, MD, Ph.D., Luna, UNC School of Medicine Department of Obstetrics and ʻO ke kino kino. "ʻOliʻoli wau i ka hiki ke koho i kahi koho lapaʻau nonhormonal hou no nā wahine e loaʻa ana i ka VMS haʻahaʻa a koʻikoʻi e pili ana me ka menopause."

ʻO nā ʻike SKYLIGHT 4, me nā hopena mai ʻelua mau hoʻokolohua lapaʻau Phase 3 koʻikoʻi, SKYLIGHT 1 ™ a me SKYLIGHT 2 ™, e hāʻawi i ka ʻikepili kumu no ka hoʻouna ʻana i nā hoʻoponopono ma US a me ʻEulopa.

ʻO ka Fezolinetant kahi mea hoʻokolokolo koho neurokinin-3 (NK3) receptor antagonist. Ke hoʻokolokolo ʻia nei ka palekana a me ka pono o ka fezolinetant a ʻaʻole i hoʻokumu ʻia. Inā ʻae ʻia e nā mana hoʻoponopono, ʻo ka fezolinetant kahi koho lapaʻau mua i ka papa, nonhormonal e hōʻemi i ka pinepine a me ka paʻakikī o ka VMS pili me ka menopause.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...